Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BGM BGM Group	$7.51 -2.2%	$9.29	$5.95 ▼ $17.17	$730.14M	1.26	42,056 shs	9,872 shs
DNTH Dianthus Therapeutics	$23.57 -5.0%	$20.60	$13.36 ▼ $32.27	$758.67M	1.43	382,629 shs	345,906 shs
GYRE Gyre Therapeutics	$7.74 -6.5%	$7.58	$6.11 ▼ $19.00	$745.46M	1.8	89,665 shs	76,302 shs
MNPR Monopar Therapeutics	$34.15 -5.3%	$37.89	$2.25 ▼ $54.30	$210.71M	1.05	34,835 shs	15,130 shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BGM BGM Group	0.00%	-3.90%	-11.23%	-43.88%	+26.86%
DNTH Dianthus Therapeutics	0.00%	-3.00%	+14.03%	+35.30%	-16.98%
GYRE Gyre Therapeutics	0.00%	-5.38%	+9.79%	-14.95%	-41.27%
MNPR Monopar Therapeutics	0.00%	+6.52%	-17.07%	+6.49%	+1,411.06%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BGM BGM Group	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
DNTH Dianthus Therapeutics	1.133 of 5 stars	3.5	0.0	0.0	0.0	2.0	0.8	0.0
GYRE Gyre Therapeutics	1.2956 of 5 stars	3.5	1.0	0.0	0.0	2.6	0.0	0.0
MNPR Monopar Therapeutics	2.6688 of 5 stars	3.4	4.0	0.0	0.0	2.2	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BGM BGM Group	0.00	N/A	N/A	N/A
DNTH Dianthus Therapeutics	3.00	Buy	$54.00	129.10% Upside
GYRE Gyre Therapeutics	3.00	Buy	$18.00	132.56% Upside
MNPR Monopar Therapeutics	2.83	Moderate Buy	$66.00	93.27% Upside

Current Analyst Ratings Breakdown

Latest MNPR, GYRE, DNTH, and BGM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/27/2025	MNPR Monopar Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$74.00
8/26/2025	GYRE Gyre Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$18.00
8/26/2025	MNPR Monopar Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$70.00
8/21/2025	DNTH Dianthus Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$34.00 ➝ $42.00
8/13/2025	MNPR Monopar Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$60.00
7/7/2025	MNPR Monopar Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$74.00
7/2/2025	DNTH Dianthus Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
6/23/2025	MNPR Monopar Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$60.00

(Data available from 8/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BGM BGM Group	$25.10M	29.09	N/A	N/A	$7.34 per share	1.02
DNTH Dianthus Therapeutics	$4.85M	156.30	N/A	N/A	$9.42 per share	2.50
GYRE Gyre Therapeutics	$102.19M	7.29	$0.20 per share	39.19	$1.34 per share	5.78
MNPR Monopar Therapeutics	N/A	N/A	N/A	N/A	$8.46 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BGM BGM Group	-$1.44M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
DNTH Dianthus Therapeutics	-$84.97M	-$3.25	N/A	N/A	N/A	-2,364.56%	-34.72%	-32.72%	11/6/2025 (Estimated)
GYRE Gyre Therapeutics	$12.09M	$0.01	774.77	∞	N/A	4.08%	7.67%	6.19%	11/12/2025 (Estimated)
MNPR Monopar Therapeutics	-$15.59M	-$3.33	N/A	N/A	N/A	N/A	-41.76%	-39.49%	11/14/2025 (Estimated)

Latest MNPR, GYRE, DNTH, and BGM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	MNPR Monopar Therapeutics	-$0.47	-$0.35	+$0.12	-$0.35	N/A	N/A
8/11/2025	Q2 2025	GYRE Gyre Therapeutics	$0.03	$0.02	-$0.01	$0.04	$30.80 million	$26.77 million
8/7/2025	Q2 2025	DNTH Dianthus Therapeutics	-$0.86	-$0.88	-$0.02	-$0.88	$0.87 million	$0.19 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BGM BGM Group	N/A	N/A	N/A	N/A	N/A
DNTH Dianthus Therapeutics	N/A	N/A	N/A	N/A	N/A
GYRE Gyre Therapeutics	N/A	N/A	N/A	N/A	N/A
MNPR Monopar Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BGM BGM Group	N/A	1.82	1.45
DNTH Dianthus Therapeutics	N/A	13.12	13.12
GYRE Gyre Therapeutics	N/A	5.40	4.87
MNPR Monopar Therapeutics	N/A	33.93	33.93

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BGM BGM Group	N/A
DNTH Dianthus Therapeutics	47.53%
GYRE Gyre Therapeutics	23.99%
MNPR Monopar Therapeutics	1.83%

Insider Ownership

Company	Insider Ownership
BGM BGM Group	58.66%
DNTH Dianthus Therapeutics	8.15%
GYRE Gyre Therapeutics	10.00%
MNPR Monopar Therapeutics	20.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BGM BGM Group	298	97.22 million	40.19 million	N/A
DNTH Dianthus Therapeutics	80	32.19 million	29.57 million	Optionable
GYRE Gyre Therapeutics	40	96.31 million	86.68 million	No Data
MNPR Monopar Therapeutics	10	6.17 million	4.91 million	Not Optionable

MNPR, GYRE, DNTH, and BGM Headlines

Recent News About These Companies

Q3 Earnings Estimate for MNPR Issued By HC Wainwright

August 30 at 6:31 AM | marketbeat.com

Analysts Issue Forecasts for MNPR Q3 Earnings

August 30 at 2:45 AM | americanbankingnews.com

Monopar Therapeutics (NASDAQ:MNPR) Given Overweight Rating at Cantor Fitzgerald

August 29 at 9:25 AM | marketbeat.com

Monopar Therapeutics' (MNPR) "Overweight" Rating Reaffirmed at Cantor Fitzgerald

August 29 at 3:02 AM | americanbankingnews.com

Affinity Asset Advisors LLC Buys Shares of 62,000 Monopar Therapeutics Inc. $MNPR

August 28 at 9:09 AM | marketbeat.com

Monopar Therapeutics (NASDAQ:MNPR) Given Buy Rating at HC Wainwright

August 28 at 8:20 AM | marketbeat.com

Monopar Therapeutics (NASDAQ:MNPR) Now Covered by HC Wainwright

August 27, 2025 | americanbankingnews.com

Monopar Therapeutics assumed with a Buy at H.C. Wainwright

August 26, 2025 | msn.com

Monopar Therapeutics management to meet with Cantor Fitzgerald

August 22, 2025 | msn.com

What is Chardan Capital's Forecast for MNPR FY2025 Earnings?

August 19, 2025 | marketbeat.com

MNPR FY2025 EPS Lifted by Brookline Capital Management

August 17, 2025 | marketbeat.com

Cantor Fitzgerald Analysts Cut Earnings Estimates for MNPR

August 17, 2025 | marketbeat.com

Monopar Therapeutics (NASDAQ:MNPR) Earns Buy Rating from Chardan Capital

August 15, 2025 | marketbeat.com

Monopar Therapeutics (NASDAQ:MNPR) Announces Earnings Results, Beats Expectations By $0.12 EPS

August 13, 2025 | marketbeat.com

Monopar Therapeutics Inc.: Monopar Therapeutics Reports Second Quarter 2025 Financial Results and Recent Developments

August 13, 2025 | finanznachrichten.de

Monopar Therapeutics Reports Increased R&D Expenses

August 13, 2025 | msn.com

Monopar Therapeutics Reports Second Quarter 2025 Financial Results and Recent Developments

August 12, 2025 | manilatimes.netM

Monopar Therapeutics Inc. Reports Q2 2025 Financial Results and Progress on ALXN1840 and MNPR-101 Clinical Trials

August 12, 2025 | quiverquant.comQ

Monopar Therapeutics Reports Second Quarter 2025 Financial Results and Recent Developments

August 12, 2025 | globenewswire.com

Monopar Therapeutics Inc. (NASDAQ:MNPR) Receives Average Rating of "Moderate Buy" from Analysts

August 12, 2025 | marketbeat.com

Monopar Therapeutics (MNPR) Projected to Post Earnings on Friday

August 1, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MNPR, GYRE, DNTH, and BGM Company Descriptions

BGM Group NASDAQ:BGM

$7.51 -0.17 (-2.21%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$7.70 +0.20 (+2.60%)

As of 08/29/2025 04:04 PM Eastern

Qilian International Holding Group Limited manufactures and distributes active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China. The company provides licorice products, including Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, a primary ingredient for medical preparation companies to produce compound licorice oral solutions. It offers Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline APIs for pharmaceutical companies to manufacture medications. In addition, the company offers TCMD products, such as Ahan antibacterial paste to treat refractory chronic skin diseases; heparin products, including heparin sodium preparations for pharmaceutical companies to produce medications for cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and Zhu Xiaochang sausage casings, which are natural food products for culinary application. Further, it provides Xiongguan organic fertilizers to improve crop yield and soil's chemical properties and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers to increased plant growth. Qilian International Holding Group Limited was incorporated in 2019 and is based in Jiuquan, the People's Republic of China.

Dianthus Therapeutics NASDAQ:DNTH

$23.57 -1.24 (-5.00%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$23.61 +0.04 (+0.17%)

As of 08/29/2025 07:57 PM Eastern

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

Gyre Therapeutics NASDAQ:GYRE

$7.74 -0.54 (-6.52%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$8.04 +0.30 (+3.81%)

As of 08/29/2025 05:16 PM Eastern

Gyre Therapeutics, Inc., a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California.

Monopar Therapeutics NASDAQ:MNPR

$34.15 -1.91 (-5.30%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$33.44 -0.70 (-2.06%)

As of 08/29/2025 06:38 PM Eastern

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time